Galapagos has been granted a patent for antibodies targeting human IL-17C, beneficial for treating inflammatory disorders like atopic dermatitis and psoriasis. The method involves administering specific antibody fragments with defined amino acid sequences to subjects suffering from such conditions. GlobalData’s report on Galapagos gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Galapagos, Peptide pharmacophores was a key innovation area identified from patents. Galapagos's grant share as of May 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of inflammatory disorders using specific antibodies
A recently granted patent (Publication Number: US11987621B2) discloses a method for treating inflammatory disorders by administering specific antibodies or antibody fragments. The method involves utilizing antibodies with defined amino acid sequences targeting human IL-17C, cynomolgus IL-17C, and mouse IL-17C. These antibodies can be human, humanized, or chimeric in nature and are administered in isolated or recombinant forms. The patent also covers pharmaceutical compositions containing these antibodies along with a pharmaceutically acceptable carrier or excipient.
Furthermore, the patent extends to methods that involve administering antibodies or antibody fragments with specific amino acid sequences, as outlined in SEQ ID NO: 17 and SEQ ID NO: 16, or SEQ ID NO: 30 and SEQ ID NO: 29. These sequences are crucial for targeting and treating inflammatory disorders in subjects. The patent provides a detailed framework for utilizing these antibodies effectively in the treatment of inflammatory conditions, showcasing the potential for novel therapeutic interventions in this field.
To know more about GlobalData’s detailed insights on Galapagos, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
